R
Ross A. Okimoto
Researcher at University of California, San Francisco
Publications - 43
Citations - 15194
Ross A. Okimoto is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Cancer & Metastasis. The author has an hindex of 23, co-authored 39 publications receiving 14243 citations. Previous affiliations of Ross A. Okimoto include Tufts Medical Center & Harvard University.
Papers
More filters
Journal ArticleDOI
Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
TL;DR: Management of newly diagnosed CML patients in the coming decade will begin to resemble antibiotic treatment of infection, with therapy individualized based on patient risk factors, co-morbidities, and tolerability, in addition to the cost of therapy as generic imatinib becomes available in 2015.
Journal ArticleDOI
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Mrinal M. Gounder,Narasimhan P. Agaram,Sally E. Trabucco,Victoria M Robinson,Richard Ferraro,S. Millis,Anita Krishnan,Jessica K. Lee,Steven Attia,Wassim Abida,Alexander Drilon,Ping Chi,Sandra P D' Angelo,Mark A. Dickson,Mary Louise Keohan,Ciara Marie Kelly,Mark Agulnik,Sant P. Chawla,Edwin Choy,Rashmi Chugh,Christian F. Meyer,Parvathi A. Myer,Jessica L Moore,Ross A. Okimoto,Raphael E. Pollock,Vinod Ravi,Arun S. Singh,Neeta Somaiah,Andrew J. Wagner,John H. Healey,Garrett M. Frampton,Jeffrey M. Venstrom,Jeffrey S. Ross,Marc Ladanyi,Samuel Singer,Murray F. Brennan,Gary K. Schwartz,Alexander J. Lazar,David Thomas,Robert G. Maki,William D. Tap,Siraj M. Ali,Dexter X. Jin +42 more
TL;DR: In this paper , targeted panel sequencing of 7494 human sarcomas representing 44 histologies was performed to identify highly recurrent and type-specific alterations that aid in diagnosis and treatment decisions.
Journal ArticleDOI
Recent advances in personalized lung cancer medicine
Ross A. Okimoto,Trever G. Bivona +1 more
TL;DR: The identification of molecular subtypes of non-small-cell lung cancer has transformed the clinical management of this disease and ability to further improve patient outcomes with biomarker-based targeted therapies will depend on a more comprehensive genetic platform that can rationally interrogate the cancer genome of an individual patient.
Journal ArticleDOI
An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.
Gayatri Premasekharan,Elizabeth Gilbert,Ross A. Okimoto,Ashiya Hamirani,Karla Lindquist,Vy Ngo,Ritu Roy,Jeffrey Hough,Matthew S. Edwards,Rosa Paz,Adam Foye,Riddhi Sood,Kirsten A. Copren,Matthew A. Gubens,Eric J. Small,Trever G. Bivona,Eric A. Collisson,Terence W. Friedlander,Pamela L. Paris +18 more
TL;DR: Fluorescence-activated cell sorting (FACS) is used in combination with the CAM assay to improve the purity of the isolated iCTCs, and iCTC enrichment enables multiple downstream genomic characterizations across different tumor types.
Journal ArticleDOI
Mytilus mitochondrial DNA contains a functional gene for a tRNASer(UCN) with a dihydrouridine arm-replacement loop and a pseudo-tRNASer(UCN) gene.
TL;DR: Northern blot and 5' RACE analyses indicated that the four-armed tRNASer(UCN) gene is transcribed into a stable RNA that includes the downstream COI sequence and is not processed into a mature tRNA.